- Buccal administration
- No first pass-hepatic degradation
- Passage through the BBB
- No exposure to plasmatic and interstitial degradation enzymes
- Increased benefit/risk ratio
- Superior pharmacokinetic profile with increased efficacy coupled with better tolerability
- Low COGs through simple but patented manufacturing process
- Finished product stable for 6 months at 40°C, and 3 years at room temperature for empty formulation
- Suitable for pediatric use
AONYS® Technology offers major benefits. Active agents are administered through a non-invasive administration (mouth deposit). At the same time, it allows drugs to reach their intracellular targets, in the brain for example, while reducing the required dose and diminishing side effects.